<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2664-2891</journal-id>
<journal-title><![CDATA[Revista científica ciencias de la salud]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. cient. cienc. salud]]></abbrev-journal-title>
<issn>2664-2891</issn>
<publisher>
<publisher-name><![CDATA[Universidad del Pacífico]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2664-28912021000200120</article-id>
<article-id pub-id-type="doi">10.53732/rccsalud/03.02.2021.120</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Reporte de un caso de plaquetopenia y trombosis secundaria a la vacuna chAdOx1 nCov-19]]></article-title>
<article-title xml:lang="en"><![CDATA[Report of a case of thrombocytopenia and thrombosis secondary to the vaccine chAdOx1 nCov-19]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montiel-Jarolin]]></surname>
<given-names><![CDATA[Dora]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[Estela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jarolin]]></surname>
<given-names><![CDATA[Magali]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Taboada]]></surname>
<given-names><![CDATA[Verónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Nacional Departamento de Medicina Interna ]]></institution>
<addr-line><![CDATA[Asunción ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>3</volume>
<numero>2</numero>
<fpage>120</fpage>
<lpage>125</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2664-28912021000200120&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2664-28912021000200120&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2664-28912021000200120&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Introducción. La vacuna contra el COVID-19, AstraZeneca, podría dar lugar al desarrollo de anticuerpos contra el factor 4 plaquetario, y desencadenar manifestaciones de trombocitopenia asociados a episodios trombóticos de localización inusual. Se presenta el caso de una paciente con plaquetopenia y trombosis asociada a la vacuna Astrazeneka internada en el Hospital Nacional en agosto 2021. Caso clínico: Mujer de 54 años de Yaguarón, recibió la vacuna Astrazeneca el 19 de junio de 2021, después de 26 días presentó múltiples lesiones equimóticas en miembros inferiores, sin trauma previo, gingivorragias, y epistaxis en moderada cantidad. Por el recuento plaquetario menor a 10.000 se la ingresa al Hospital. No recibió heparina. Los signos vitales normales, IMC 25, recuento de plaquetas &lt;10.000/ mm3, tiempo de protrombina 89%, tiempo parcial de tromboplastina activada 28 segundos, otros parámetros hematológicos normales. Anticuerpo antinuclear (ANA), anti DNA, antiproteinasa 3, anti mieloperoxidasa: negativos; c3 y c4 normal. Serología IgM negativa para toxoplasmosis, citomegalovirus, herpes, rubeola, Chagas, VIH, hepatitis B, C. Ecodopler venoso de miembros inferiores muestra una trombosis de la vena safena parva bilateral. Es tratada con pulsos de metilprednisolona 1g/3 días, seguida de prednisona vía oral 1mg kg/p//día, con recuperación del recuento de las plaquetas. No se realizó prueba anticuerpo anti factor 4 plaquetario. Conclusión: Por la relación temporal entre la administración de la vacuna y la aparición de la plaquetopenia y trombosis, se podría considerar como un efecto adverso de la vacuna Astrazeneka.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Introduction. The COVID-19 vaccine, AstraZeneca, may lead to the development of antibodies against platelet factor 4, and trigger manifestations of thrombocytopenia associated with thrombotic events of unusual location. A case of a patient with thrombosis associated with the Astrazeneka vaccine and admitted to the National Hospital in August 2021 is presented. Clinical case: A 54-year-old woman from Yaguaron, received the Astrazeneca vaccine on June 19th, 2021, 26 days later she presented multiple ecchymotic lesions in lower limbs with no history of trauma, gingivorrhagia, epistaxis in moderate quantity. Due to a platelet count lower than 10,000/ mm3, she was admitted to the Hospital. She did not receive heparin. Vital signs were normal, BMI 25, platelet count &lt;10,000 per mm3, prothrombin time 89%, activated partial thromboplastin time 28 seconds, other hematological parameters normal. Antinuclear antibody (ANA), anti DNA, antiproteinase 3, anti myeloperoxidase: negative, c3 and c4 normal. Negative IgM serology for toxoplasmosis, cytomegalovirus, herpes, rubella, Chagas, HIV, hepatitis B, C. Lower limb venous echodpler shows bilateral parva saphenous vein thrombosis. The patient is treated with pulses of methylprednisolone 1g / 3 days, followed by oral prednisone 1mg kg / p / day, with recovery of platelets. An anti-platelet factor 4 antibody test was not performed. Conclusion: due to the temporal relationship between the administration of the vaccine and the appearance of thrombocytopenia and thrombosis, this case may be considered as an adverse effect of the Astrazeneka vaccine.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[trombocitopenia]]></kwd>
<kwd lng="es"><![CDATA[trombosis]]></kwd>
<kwd lng="es"><![CDATA[vacuna]]></kwd>
<kwd lng="es"><![CDATA[efecto secundario]]></kwd>
<kwd lng="en"><![CDATA[thrombocytopenia]]></kwd>
<kwd lng="en"><![CDATA[thrombosis]]></kwd>
<kwd lng="en"><![CDATA[vaccine]]></kwd>
<kwd lng="en"><![CDATA[secondary effect]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharifian-Dorche]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bahmanyar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sharifian-Dorche]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mohammadi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Nomovi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mowla]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review]]></article-title>
<source><![CDATA[J Neurol Sci]]></source>
<year>2021</year>
<volume>428</volume>
<page-range>117607</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greinacher]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thiele]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Warkentin]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Weisser]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kyrle]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Eichinger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>384</volume>
<page-range>2094-101</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Pharmacovigilance Risk Assessment Committee (PRAC). Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant])]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scully]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lown]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Poles]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination]]></article-title>
<collab>Levi M et al</collab>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>384</volume>
<page-range>2202-11</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schultz]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
<name>
<surname><![CDATA[Sørvoll]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
<name>
<surname><![CDATA[Michelsen]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Munthe]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Lund-Johansen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ahlen]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2021</year>
<volume>384</volume>
<page-range>2124-30</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez van Kammen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Heldner]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Brodard]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2021</year>
<volume>326</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>332-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Programa Ampliado de Inmunizaciones Paraguay</collab>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Luz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Niehaus]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bhogal]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bäzner]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Henkes]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombocytopenia and Intracranial Venous Sinus Thrombosis after &amp;raquo;,» &amp;reg;,® &amp;sect;,§ &amp;shy;,­ &amp;sup1;,¹ &amp;sup2;,² &amp;sup3;,³ &amp;szlig;,ß &amp;THORN;,Þ &amp;thorn;,þ &amp;times;,× &amp;Uacute;,Ú &amp;uacute;,ú &amp;Ucirc;,Û &amp;ucirc;,û &amp;Ugrave;,Ù &amp;ugrave;,ù &amp;uml;,¨ &amp;Uuml;,Ü &amp;uuml;,ü &amp;Yacute;,Ý &amp;yacute;,ý &amp;yen;,¥ &amp;yuml;,ÿ &amp;para;,¶ COVID-19 Vaccine AstraZeneca &amp;raquo;,» &amp;reg;,® &amp;sect;,§ &amp;shy;,­ &amp;sup1;,¹ &amp;sup2;,² &amp;sup3;,³ &amp;szlig;,ß &amp;THORN;,Þ &amp;thorn;,þ &amp;times;,× &amp;Uacute;,Ú &amp;uacute;,ú &amp;Ucirc;,Û &amp;ucirc;,û &amp;Ugrave;,Ù &amp;ugrave;,ù &amp;uml;,¨ &amp;Uuml;,Ü &amp;uuml;,ü &amp;Yacute;,Ý &amp;yacute;,ý &amp;yen;,¥ &amp;yuml;,ÿ &amp;para;,¶ Exposure]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2021</year>
<volume>10</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1599</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>OMS</collab>
<source><![CDATA[Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19)]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
